NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $22.33 -0.18 (-0.80%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$22.52 +0.19 (+0.87%) As of 10/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cue Biopharma Stock (NASDAQ:CUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$21.60▼$22.7450-Day Range$22.33▼$37.8452-Week Range$4.97▼$45.50Volume109,894 shsAverage Volume453,049 shsMarket Capitalization$162.21 millionP/E RatioN/ADividend YieldN/APrice Target$83.00Consensus RatingHold Company Overview Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies. Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens. Its lead programs have included CUE-101, an investigational therapy designed to stimulate immune responses against HPV16-positive cancers, and CUE-102, which targets the Wilms’ tumor 1 antigen found in several tumor types. The company has also explored additional candidates and applications of its platform in oncology and immune-mediated diseases. Founded in 2014 and headquartered in Boston, Massachusetts, Cue Biopharma has advanced its candidates through clinical development in the United States. Dan Passeri, a co-founder of the company, has served as its chief executive officer. As a clinical-stage biotechnology company, Cue Biopharma’s programs remain investigational and are subject to clinical and regulatory evaluation.AI Generated. May Contain Errors. Read More Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCUE MarketRank™: Cue Biopharma scored higher than 44% of companies evaluated by MarketBeat, and ranked 527th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingCue Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCue Biopharma has a consensus price target of $83.00, representing about 271.7% upside from its current price of $22.33.Amount of Analyst CoverageCue Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($21.79) to ($8.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.35% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 2.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently increased by 4.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 3 articles on an average week.Search Interest3 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,041,555.00 in company stock.Percentage Held by Insiders14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Stock News HeadlinesReviewing Cue Biopharma (NASDAQ:CUE) and Coya Therapeutics (NASDAQ:COYA)October 3, 2026 | americanbankingnews.comCue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?September 26, 2026 | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | Investors Alley (Ad)Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeptember 21, 2026 | seekingalpha.comCue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug CandidateSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial ResultsSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump With Positive Results in Chronic Spontaneous Urticaria TrialSeptember 21, 2026 | marketwatch.comCue Biopharma plummets on phase 2 data for chronic spontaneous urticaria assetSeptember 21, 2026 | msn.comSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $274.86 on January 1st, 2026. Since then, CUE shares have decreased by 91.9% and is now trading at $22.33. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) released its quarterly earnings data on Friday, August, 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by $22.45. The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3 million. Cue Biopharma had a negative trailing twelve-month return on equity of 620.06% and a negative net margin of 435.83%. When did Cue Biopharma's stock split? Cue Biopharma's stock reverse split on the morning of Thursday, April 23rd 2026.The 1-30 reverse split was announced on Wednesday, April 22nd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 22nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cue Biopharma IPO? Cue Biopharma (CUE) raised $62 million in an initial public offering (IPO) on Tuesday, January 2nd 2018. The company issued 8,820,710 shares at $6.00-$8.00 per share. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings8/14/2026Today10/08/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CUE's financial health is in the Green zone, according to TradeSmith. CUE has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for Cue Biopharma$83.00 High Price Target$83.00 Low Price Target$83.00 Potential Upside/Downside+271.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($27.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.60 million Net Margins-435.83% Pretax Margin-434.50% Return on Equity-620.06% Return on Assets-291.15% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual Sales$37.66 million Price / Sales4.31 Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book2.22Miscellaneous Outstanding Shares7,264,000Free Float6,206,000Market Cap$162.21 million OptionableOptionable Beta2.62 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CUE) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
